

DEXCOM INC  
Form 8-K  
June 01, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): May 31, 2007**

**DexCom, Inc.**

(Exact Name of the Registrant as Specified in Its Charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**000-51222**

(Commission File Number)

**33-0857544**

(IRS Employer Identification No.)

**5555 Oberlin Drive, San Diego, CA**  
(Address of Principal Executive Offices)

**92121**  
(Zip Code)

**(858) 200-0200**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2)

- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01: Regulation FD Disclosure.**

On Thursday May 31, 2007, DexCom, Inc. ( DexCom ) received Food and Drug Administration approval for its second generation continuous glucose monitoring system designed for seven days of continuous use.

**Item 9.01: Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description of Exhibit
99.01	Press release dated May 31, 2007 regarding Food and Drug Administration approval of DexCom's seven day continuous glucose monitoring system.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DEXCOM, INC.

By: */s/ Steven R. Pacelli*  
Steven R. Pacelli  
Vice President of Legal Affairs

Date: May 31, 2007

3

---

**Exhibit Index**

<b>Number</b>	<b>Description</b>
99.01	Press release dated May 31, 2007 regarding Food and Drug Administration approval of DexCom's seven day continuous glucose monitoring system.

4

---